Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients

Background: Immunotherapy plus tyrosine kinase inhibitor (IO-TKI) has become the first-line management for metastatic renal cell carcinoma (RCC), despite the absence of biomarkers. Recently, pyrroline-5-carboxylate reductase 1 (PYCR1) and proline metabolism have been reported regulatory roles in the...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xianglai Xu, Ying Wang, Xinyu Hu, Yanjun Zhu, Jiajun Wang, Jianming Guo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2023-09-01
Colecção:	Neoplasia: An International Journal for Oncology Research
Assuntos:	Renal cell carcinoma PYCR1 Immune checkpoint inhibition plus tyrosine kinase inhibition T cell dysfunction
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1476558623000441
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!